skip to main content

Valproate PPP gap — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

ModerateAdverse Drug Reactions and Drug SafetyValproate PPP gapGPhC CRA

A woman of childbearing potential on valproate has not had annual specialist review or risk acknowledgement this year. What is the most appropriate action?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Urgently clarify specialist review and pregnancy prevention status

This scenario assesses Valproate PPP gap in a UK pharmacy practice context. Valproate risk-minimisation requirements need active checking at supply. The best answer is Urgently clarify specialist review and pregnancy prevention status because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.

Reference: MHRA Drug Safety Update; BNF